Shenzhen University General Hospital is the lead sponsor of 11 current clinical trials in our China register. 10 are recruiting patients now. The most common phase is Phase 1/2. The drugs named most often in its trials are Gemcitabine and Gemcitabine alone. The most-studied condition is Relapsed/Refractory B-cell Lymphoma.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma
NCT06644443 · Multiple Myeloma in Relapse
|
Phase 1/2 | Recruiting | 2023-07 | China |
|
Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell Lymphoma
NCT07097207 · ClinicalTrials.gov ↗ · Relapsed/Refractory B-cell Lymphoma
|
Phase 1/2 | Recruiting | 2023-10 | China |
|
Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
NCT07563179 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Relapse/Recurrence
|
Phase 2 | Recruiting | 2026-04 | China |
|
Study of NY-ESO-1 TCR-T in Advanced Soft Tissue Sarcoma
NCT05620693 · ClinicalTrials.gov ↗ · Advanced Soft-tissue Sarcoma
|
Not applicable | Recruiting | 2022-11 | China |
|
Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies
NCT07584889 · ClinicalTrials.gov ↗ · B Cell Lymphoma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
|
Phase 1/2 | Recruiting | 2024-04 | China |
|
CD7 CAR-T Cells in T-cell Lymphoma/Leukemia
NCT05620680 · ClinicalTrials.gov ↗ · T Lymphoblastic Leukemia/Lymphoma
|
Not applicable | Recruiting | 2022-10 | China |
|
Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T
NCT05620732 · ClinicalTrials.gov ↗ · Advanced Pancreatic Carcinoma, Advanced Gastric Carcinoma
|
Not applicable | Recruiting | 2022-10 | China |
|
Efficacy and Safety of CD19/CD20 CAR/TRuC-T in Relapsed/Refractory B-Cell Lymphoma
NCT07508605 · ClinicalTrials.gov ↗ · Relapsed/Refractory B-cell Lymphoma
|
Phase 1/2 | Recruiting | 2025-01 | China |
|
Efficacy and Safety of MSLN CAR-T in Advanced Malignant Tumors
NCT07399769 · ClinicalTrials.gov ↗ · Advanced Solid Malignant Tumors (With Positive Expression of MSLN in Tumor Tissue)
|
Phase 1/2 | Recruiting | 2024-01 | China |
|
Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma
NCT05620706 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma
|
Not applicable | Recruiting | 2022-11 | China |
|
Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients
NCT06234072 · ClinicalTrials.gov ↗ · Pancreatic Cancer
Drugs: Gemcitabine, Gemcitabine alone |
Phase 2 | Not yet open | 2024-02 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 11 | 10 |
A trial with sites in more than one country appears in each of those registers.
| Sponsor | Trials |
|---|---|
| YANRU WANG | 1 |
Sponsors with the most current trials registered for this condition.
Shenzhen University General Hospital is the lead sponsor of 11 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 10 of its 11 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 2 drugs and biologicals as interventions. The most frequent are Gemcitabine (1) and Gemcitabine alone (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.